Due to their inhibitory effects on T cell activation and function, DPP-4 inhibitors (DPP-4i) have been successfully evaluated in vivo as immunosuppressive therapies using animal models of rheumatoid arthritis (RA), multiple sclerosis (MS), and transplantation
Allow more time between drinking and driving, operating machinery, or any safety-sensitive activity
10.1038/s41577-020-00478-8 Nat Rev Immunol
It is a normal reaction as the body adjusts without the medication
Clinical Evidence: What the Data Shows Phase 3 Trial Results (Zepbound Studies) The REFRAME and related trials demonstrated: Weight Loss Average: 22.5% body weight reduction at 68 weeks Range: 18-28% depending on population Significantly exceeds tirzepatide (21% at comparable doses) Body Composition Preferential loss of visceral fat (the dangerous kind) Better preservation of lean muscle vs
While neither liraglutide nor semaglutide is FDA-approved for cardiovascular protection, research suggests both may help lower the risk of major heart-related events like heart attack, stroke, or cardiovascular death in people with type 2 diabetes